Oppenheimer Maintains Outperform on Cognition Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Cognition Therapeutics (NASDAQ:CGTX) and keeps the price target at $9.
March 27, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating on Cognition Therapeutics with a $9 price target.
The reaffirmation of an Outperform rating and a $9 price target by a reputable analyst like Jay Olson from Oppenheimer is likely to instill confidence among investors and could positively influence the stock price of Cognition Therapeutics in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100